Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PARK7
is involved in many key cellular processes, including cell proliferation, transcriptional regulation, cellular differentiation, oxidative stress protection, and mitochondrial function maintenance. Deregulation of
PARK7
has been implicated in the pathogenesis of various human diseases, including cancer. Here, we aimed to clarify the effect of
PARK7
on stemness and radioresistance of glioblastoma stem cells (GSCs). Serum differentiation and magnetic cell sorting of GSCs revealed that
PARK7
was preferentially expressed in GSCs rather than differentiated GSCs. Immunohistochemical staining showed enhanced expression of
PARK7
in
glioma
tissues compared to that in normal brain tissues. shRNA-mediated knockdown of
PARK7
inhibited the self-renewal activity of GSCs in vitro, as evidenced by the results of neurosphere formation, limiting dilution, and soft-agar clonogenic assays. In addition,
PARK7
knockdown suppressed GSC invasion and enhanced GSC sensitivity to ionizing radiation (IR).
PARK7
knockdown suppressed expression of GSC signatures including nestin, epidermal growth factor receptor variant III (EGFRvIII), SOX2, NOTCH1, and OCT4. Contrarily, overexpression of
PARK7
in CD133
-
non-GSCs increased self-renewal activities, migration, and IR resistance, and rescued the reduction of GSC factors under shPARK7-transfected and serum-differentiation conditions. Intriguingly,
PARK7
acted as a co-chaperone of HSP90 by binding to it, protecting EGFRvIII from proteasomal degradation. Knockdown of
PARK7
increased the production of reactive oxygen species, inducing partial apoptosis and enhancing IR sensitivity in GSCs. Finally,
PARK7
knockdown increased mouse survival and IR sensitivity in vivo. Based on these data, we propose that
PARK7
plays a pivotal role in the maintenance of stemness and therapeutic resistance in GSCs.
...
PMID:PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III. 3318 96